Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

High-dose radiation beams target liver tumors with precision

NCT ID NCT01165346

Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a high-precision radiation treatment called stereotaxic radiotherapy (CyberKnife) in 44 adults with a single liver cancer tumor. The goal was to stop the tumor from growing for at least 18 months. Participants received three high-dose radiation sessions over 8-10 days. The approach is for patients who cannot have standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

44 people

The number who actually took part.

Started

Aug 2009

Finished

Apr 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Primitive liver cancer (hepatocellular carcinoma), proved by histology or diagnostic according to BCLC criteria * T1-3 N0 M0 * With only one intra hepatic lesion and dimensions between 1 cm and 6 cm (IRM or hepatic scanner) * Stereotaxic radiotherapy treatment approved in multidisciplinary consultation, the patient being rejected for standard therapeutic * Age \>= 18 ans * Previous anti tumoral treatment allowed but suspended since at least 15 days before the inclusion * OMS =\< 2 * Portal thrombosis allowed * Portal high blood pressure allowed * No contraindication of fiducials implantation, hemostasis disorders must be treated before the implantation * In case of underlying cirrhosis, only the Child-Pugh A is allowed * Life expectancy \>= 12 weeks * Women must have an active contraception during all the study * Patient affiliated to health insurance * Patient must sign the consent Exclusion Criteria: * T4 * Cirrhosis Child B and C * Hepatic lesion \< 1 cm or \> 6 cm * 2 hepatic lesions or more * Recurrent or metastatic disease * Patient already included in another therapeutic trial with an experimental molecule * Allergy to gold * Pregnant women or susceptible to be pregnant or breastfeeding * Unable for medical follow-up (geographic, social or mental reasons)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • Centre Alexis Vautrin

    Vandœuvre-lès-Nancy, 54500, France

  • Centre François Baclesse

    Caen, 14076, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Centre Oscar LAMBRET

    Lille, 59020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.